Evidence map›Paper›PMID 42182515›Full record

ArticlebioRxiv : the preprint server for biology2026

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in

Yingxiao Shi, Alexander Savchenko, Jan Christoph Brase, Brendan Reardon, Cora A Ricker, Jihye Park, Giuseppe Tarantino, Michael P Manos, Amy Y Huang, Eliezer M Van Allen and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yingxiao ShiDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2783-9642
Alexander SavchenkoNovartis, Cambridge, MA, USA.ORCID 0000-0002-6036-0775
Jan Christoph BraseNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0002-1325-2528
Brendan ReardonDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1716-5720
Cora A RickerDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1202-5603
Jihye ParkDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4451-2046
Giuseppe TarantinoDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-6078-6856
Michael P ManosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0841-207X
Amy Y HuangDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-6646-6503
Eliezer M Van AllenDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0201-4444
Levi A GarrawayRoche/Genentech, South San Francisco, CA, USA.ORCID 0000-0003-3739-0471
Keith T FlahertyMassachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-3402-0478
David LiuDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0346-5033

Funding

Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyK08CA234458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LIU, DAVID · 2018 to 2022
$1.2M
NCI NIH HHS K08 CA234458
6 · The paper itself

Abstract

BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti-PD-1/anti-CTLA-4) have transformed the treatment of

Identifiers

PMID42182515
PMCPMC13192995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.